By Mark Terry

LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.

Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will use LineaRx’s linear DNA technology.